Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates
12:13pm, Tuesday, 09'th May 2023
Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2023 Earnings Call Transcript
08:03pm, Monday, 08'th May 2023
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executiv
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
07:02pm, Monday, 08'th May 2023
Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.70 per share a year ago.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
09:53am, Monday, 24'th Apr 2023
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
09:04am, Tuesday, 11'th Apr 2023
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30
Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 29'th Mar 2023 Zacks Investment Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?
01:40pm, Wednesday, 29'th Mar 2023 Zacks Investment Research
Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Analyst Ratings for ACADIA Pharmaceuticals
01:00pm, Monday, 20'th Mar 2023 Benzinga
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
3
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
03:20pm, Thursday, 16'th Mar 2023 Zacks Investment Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?
06:43am, Wednesday, 15'th Mar 2023 Zacks Investment Research
Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?
03:54am, Wednesday, 15'th Mar 2023
Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
12:28pm, Tuesday, 14'th Mar 2023 Benzinga
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.
Daybue is the first and only drug approv
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
12:11pm, Tuesday, 14'th Mar 2023 Benzinga
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 o
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
02:19pm, Monday, 13'th Mar 2023 Zacks Investment Research
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Dayb
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
12:19pm, Monday, 13'th Mar 2023 Benzinga
Gainers
Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approx
